Co-LAB AccelBio
AccelBio is a collaborative laboratory dedicated to advancing biomedical science from research to market. It focuses on drug discovery, innovation, and collaboration among academia, startups, industry, and research institutions to develop new therapeutics and healthcare solutions. The organization supports projects in various therapeutic areas, fosters open innovation, and actively participates in international biotech events and initiatives to promote scientific progress and industry partnerships.
Industries
Nr. of Employees
small (1-50)
Co-LAB AccelBio
Services
Competitive calls providing small-scale awards and structured support (experiments and value-creation plans) to advance research projects toward preclinical candidate stage.
Collaborative access or contract research using human pluripotent stem cell-derived organoids and 3D tissue models for disease modelling, toxicity screening and drug testing.
Design and execution of large-scale screening campaigns using high-content imaging and phenotypic assays, including hit validation workflows.
Computational analysis, integration and visualization of transcriptomic, proteomic and metabolomic datasets to support target identification and biomarker discovery.
Development and validation of analytical assays for small molecules and biomolecules using LC-MS and NMR for metabolomics, proteomics and quantitative studies.
In silico compound prioritization, structure-based modelling and computational chemistry to support hit-to-lead optimization.
Competitive calls providing small-scale awards and structured support (experiments and value-creation plans) to advance research projects toward preclinical candidate stage.
Collaborative access or contract research using human pluripotent stem cell-derived organoids and 3D tissue models for disease modelling, toxicity screening and drug testing.
Design and execution of large-scale screening campaigns using high-content imaging and phenotypic assays, including hit validation workflows.
Computational analysis, integration and visualization of transcriptomic, proteomic and metabolomic datasets to support target identification and biomarker discovery.
Development and validation of analytical assays for small molecules and biomolecules using LC-MS and NMR for metabolomics, proteomics and quantitative studies.
In silico compound prioritization, structure-based modelling and computational chemistry to support hit-to-lead optimization.
Expertise Areas
- Drug discovery and preclinical development
- Advanced in vitro models and organoids
- Cardiac organoid development and cardiac tissue modelling
- High-throughput and high-content screening
Key Technologies
- Organoid and 3D stem cell-derived models
- High-throughput screening (HTS)
- High-content imaging and microscopy (HCS)
- Multi-omics integration (transcriptomics, proteomics, metabolomics)
News & Updates
A pivotal event bringing together Portuguese R&D, industry, and investors to explore how open innovation can advance healthcare solutions.
Participation in the Science and Technology Exhibition, sharing insights into drug discovery and development services, and engaging with attendees.
First IAB meeting to discuss strategic priorities, objectives, and insights for the future of CoLAB AccelBio.
A groundbreaking project in collaboration with Marc Veldhoen’s team to develop targeted immune modulation strategies for infectious and inflammatory diseases.
Participation in major biotech events to explore synergies, unveil platforms, and foster collaborations to accelerate drug development.
Recognition of LiMM Therapeutics and BSIM Therapeutics as leading biotech companies in Portugal by Labiotech.eu.
A pivotal event bringing together Portuguese R&D, industry, and investors to explore how open innovation can advance healthcare solutions.
Participation in the Science and Technology Exhibition, sharing insights into drug discovery and development services, and engaging with attendees.
First IAB meeting to discuss strategic priorities, objectives, and insights for the future of CoLAB AccelBio.
A groundbreaking project in collaboration with Marc Veldhoen’s team to develop targeted immune modulation strategies for infectious and inflammatory diseases.
Participation in major biotech events to explore synergies, unveil platforms, and foster collaborations to accelerate drug development.
Recognition of LiMM Therapeutics and BSIM Therapeutics as leading biotech companies in Portugal by Labiotech.eu.